BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) skyrocketed 51.22% on Monday after the company disclosed it successfully completed its Phase 1 clinical trial of BCX4161 showing that overall, 87 healthy volunteers completed the study. The company also said it expects to initiate a Phase 2a trial in hereditary angioedema patients in 2013.
TrovaGene Inc (NASDAQ:TROV) climbed 21.31% after revealing that results emerging from ongoing clinical studies have confirmed the broad applicability of Trovagene technology across a variety of cancer types, and the successful development of a molecular diagnostic test capable of detecting and quantifying oncogene mutations from a simple urine specimen.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) rose 16.00%, continuing to move higher on FDA acceptance of NORTHERA(TM) (droxidopa) NDA Resubmission.
Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) added 7.08% as the company approaches its earnings release later this month.
Sarepta Therapeutics Inc (NASDAQ:SRPT) rose 4.51%, possibly in sympathy with a sharply rise in BCRX and hopes that it will report better-than-expected earnings, when it releases quarterly report in August.
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) advanced 3.66%, rebounding from declines after reaching ex-date last week.
VIVUS, Inc. (NASDAQ:VVUS) disclosed late Monday its Board of Directors has appointed Michael Astrue to serve as its Chairman and Anthony Zook to serve as its Chief Executive Officer, effective immediately.
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) was up amid news that AstraZeneca Plc (AZN), Pfizer Inc. and Novartis AG (NOVN) are among the suitors preparing bids for ONXX.
On the negative side, CEL-SCI Corporation (NYSEMKT:CVM) plunged 17.09%, suffering new low after the company report on a communication from staff of its current listing exchange that it considered the company to be noncompliant with certain listing requirements based on its quarterly report for the period ended March 31, 2013.
Celsion Corporation (NASDAQ:CLSN) fell 8.80% on profit taking following Friday’s gain of 16.49% as the company and Zhejiang Hisun Pharmaceutical Company Ltd. have signed a Memorandum of Understanding to pursue ongoing collaborations for the continued clinical development of ThermoDox® as well as the technology transfer relating to the commercial manufacture of ThermoDox for the greater China territory.
Mast Therapeutics Inc (NYSEMKT:MSTX) dropped 4%, giving back some of gains after Vista Partners declared that it has updated coverage on MSTX with a twelve-month price target of $2.25.
Nektar Therapeutics (NASDAQ:NKTR) and Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) were down despite no company-specific news.